

Immunological imprinting by seasonal coronaviruses and previous herpesvirus infections in patients with long COVID


W. Ashwin Mak^{1,2}, Daphne Wapperom¹, Anne-Lotte Redel^{3,4}, Johannes G.M. Koeleman¹, Pieter W. Smit^{1,5}, Wai-Kwan Lam-Tse⁶, Tom van der Poll², Hung-Jen Chen², Jeroen den Dunnen², Gert-Jan Braunstaal^{3,4}, David S.Y. Ong^{1,7}

¹Department of Medical Microbiology and Infection Control, Franciscus Hospital, Rotterdam; ²Center for Experimental and Molecular Medicine, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, Amsterdam; ³Department of Pulmonology, Franciscus Hospital, Rotterdam; ⁴Department of Respiratory Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam; ⁵Department of Medical Microbiology, Molecular Diagnostics Unit, Maastad Hospital, Rotterdam; ⁶Department of Rheumatology and Clinical Immunology, Franciscus Hospital, Rotterdam; ⁷Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht; all the Netherlands


1. Introduction

- Up to 10% of individuals experience persistent symptoms after SARS-CoV-2 infection, termed **long COVID (LC)**, with a global economic impact estimated at 3 trillion USD.
- LC is a post-acute infection syndrome characterized by a wide spectrum of multi-organ symptoms, including fatigue, post-exertional malaise, neurocognitive impairments (brain fog), and many others.
- Proposed mechanisms underlying LC include SARS-CoV-2 persistence, herpesvirus reactivation, and autoimmunity.
- This study explores whether immunological imprinting from endemic coronaviruses, prior herpesvirus infections and reactivations, and autoimmunity contribute to LC.


2. Methods




3. Increased endemic betacoronavirus anti-Spike IgG levels in LC patients



4. Lower SARS-CoV-2 anti-Spike IgG and IgA, but increased anti-Nucleocapsid IgG and anti-Spike IgM levels in LC patients




5. LC patients have decreased CMV p65 IgG levels which associate with fatigue severity



Serum antibody levels against human herpesviruses in HC and LC cohorts. (A) Seropositivity rates for Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus type 1 (HSV1) and type 2 (HSV2), and human herpesvirus 6 (HHV6). (B) Mean fold change of antibody levels specific to various herpesvirus antigens. Mann-Whitney U with adjusted p values for multiple comparisons (**p<0.01). (C) Correlation between CMV p65 IgG levels and fatigue severity in LC patients as assessed with the FAS questionnaire. Spearman's rank correlation.

6. LC patients do not express specific anti-nuclear autoantibodies



Serum ANA profile in HC and LC cohorts. (A) Heatmap showing quantitative levels of ANAs related to several systemic autoimmune diseases. (B) The number of positive ANAs in HC and LC patients.

7. Conclusion

- LC patients exhibit altered coronavirus antibody profiles, potentially driven by impaired isotype switching of SARS-CoV-2-specific antibodies and immunological imprinting (original antigenic sin) by prior betacoronavirus infections. These mechanisms may underlie the observed reduction in S1-specific IgG levels, contributing to viral or antigen persistence in LC.
- Lower CMV p65 IgG levels correlate with increased fatigue severity, highlighting a potential link between herpesvirus-specific immunity and LC symptoms.
- Further investigation into these mechanisms is essential to elucidate LC pathophysiology and develop therapeutic strategies.